Angiocentric lymphoma
Angiocentric lymphoma is a rare type of non-Hodgkin lymphoma that primarily affects the nasal cavity and paranasal sinuses. It is also known as extranodal NK/T-cell lymphoma, nasal type. This disease is characterized by the abnormal proliferation of lymphocytes, a type of white blood cell, in an angiocentric pattern (surrounding and invading blood vessels).
Epidemiology[edit | edit source]
Angiocentric lymphoma is more common in East Asia and Central and South America than in North America and Europe. It affects more males than females and is most commonly diagnosed in middle-aged adults, although it can occur at any age.
Pathogenesis[edit | edit source]
The pathogenesis of angiocentric lymphoma is not fully understood. It is associated with Epstein-Barr virus (EBV) infection, suggesting that EBV may play a role in the development of this disease. The lymphoma cells in angiocentric lymphoma are usually of the T-cell or natural killer (NK) cell type, and they often express CD56, a marker of NK cells.
Clinical Features[edit | edit source]
Patients with angiocentric lymphoma typically present with nasal obstruction, recurrent epistaxis (nosebleeds), and facial swelling. Other symptoms may include fever, weight loss, and night sweats. The disease often invades adjacent structures, leading to eye symptoms, skin lesions, and neurological symptoms.
Diagnosis[edit | edit source]
The diagnosis of angiocentric lymphoma is based on histopathological examination of a biopsy specimen. The lymphoma cells show an angiocentric and angiodestructive growth pattern, leading to necrosis of the affected tissue. Immunohistochemical staining is used to determine the cell type and the presence of EBV.
Treatment[edit | edit source]
The treatment of angiocentric lymphoma includes chemotherapy, radiation therapy, and in some cases, stem cell transplantation. The choice of treatment depends on the stage of the disease, the patient's overall health, and other factors.
Prognosis[edit | edit source]
The prognosis of angiocentric lymphoma is generally poor, with a 5-year survival rate of less than 50%. Factors that are associated with a worse prognosis include advanced stage of the disease, high International Prognostic Index score, and presence of systemic symptoms.
See Also[edit | edit source]
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD
